本文選題：多巴酚丁胺 + 順鉑　； 參考：《山西醫(yī)科大學》2017年碩士論文

【摘要】：目的:研究多巴酚丁胺單獨或聯(lián)合順鉑(DDP)對人肺腺癌細胞A549生物學行為的影響,探討多巴酚丁胺和DDP聯(lián)合運用治療肺腺癌的可能性。方法:選取人肺腺癌細胞A549,并將細胞分成對照(control)組、多巴酚丁胺組、DDP組和聯(lián)合組(多巴酚丁胺+DDP),進行如下實驗:(1)CCK-8法:對加入多巴酚丁胺(0、7.5、15、30、60、120μmol/L)或DDP(0、1.25、2.5、5、10、20μg/ml)分別干預24、48、72h后A549細胞的增殖水平進行檢測,并選擇合適的作用濃度和時間;(2)劃痕愈合實驗:檢測各組A549細胞遷移能力的變化;(3)Transwell侵襲實驗:對各組A549細胞侵襲能力的變化進行檢測;(4)流式細胞術:對各組細胞凋亡率的變化進行檢測;(5)Western Blot技術:對各組細胞Yes相關蛋白(YAP)和磷酸化YAP(P-YAP)的表達水平進行檢測。結果:(1)細胞增殖水平的檢測:多巴酚丁胺和DDP都可以抑制A549細胞的增殖,細胞的增殖抑制率呈濃度和時間依賴性增加(P0.05)。(2)細胞遷移能力的檢測:與control組相比,多巴酚丁胺組A549細胞的劃痕愈合率降低(P0.05);與多巴酚丁胺或DDP單獨作用組相比,聯(lián)合組A549細胞的劃痕愈合率降低(P0.05)。(3)細胞侵襲能力的檢測:與control相比,多巴酚丁胺組的穿膜細胞數(shù)減少(P0.05);與多巴酚丁胺或DDP單獨作用組相比,聯(lián)合組的穿膜細胞數(shù)減少(P0.05)。(4)細胞凋亡率的檢測:與control組相比,多巴酚丁胺組A549細胞的凋亡率增加(P0.05);與多巴酚丁胺或DDP單獨作用組相比,聯(lián)合組A549細胞的凋亡率增加(P0.05)。(5)YAP和P-YAP蛋白表達水平的檢測:與control組相比,多巴酚丁胺組和順鉑組A549細胞YAP的表達都減少,并且P-YAP的表達都增加(P0.05);與多巴酚丁胺組相比,聯(lián)合組A549細胞YAP的表達減少,并且P-YAP的表達增加(P0.05)。結論:多巴酚丁胺可能是通過抑制人肺腺癌A549細胞YAP蛋白的表達協(xié)同增強DDP的作用,進而抑制A549細胞的增殖、遷移和侵襲轉移能力,并促進A549細胞的凋亡。
[Abstract]:Aim: to study the effect of dobutamine alone or in combination with cisplatin (DDP) on the biological behavior of human lung adenocarcinoma cell line A549 and to explore the possibility of dobutamine combined with DDP in the treatment of lung adenocarcinoma. Methods: human lung adenocarcinoma cell A549 was selected and divided into control (control) group. Dobutamine group and dobutamine group (dobutamine group) were tested as follows: (1) CCK-8 method: the proliferation level of A549 cells was detected by adding dobutamine (07.5N 15303060120 渭 mol / L) or DDP (0 1. 252.5A1020 渭 g/ml). And select the appropriate concentration and time; (2) scratch healing test: detect the change of migration ability of A549 cells in each group; (3) Transwell invasion test: to detect the change of invasion ability of A549 cells in each group; (4) flow cytometry: to detect the changes of cell migration ability of A549 cells in each group; (4) flow cytometry: to detect the migration ability of A549 cells in each group. (5) Western blot: the expression levels of YAP and phosphorylated YAP (P-YAP) were detected. Results: (1) the level of cell proliferation: dobutamine and DDP could inhibit the proliferation of A549 cells. The inhibition rate of cell proliferation was increased in a concentration and time dependent manner (P0.05). Compared with control group, dobutamine and DDP could inhibit the proliferation of A549 cells in a concentration-and time-dependent manner. Compared with dobutamine or dobutamine alone, the rate of scratch healing of A549 cells in dobutamine group was lower than that in dobutamine alone group (P0.05). (3). Compared with dobutamine or dobutamine alone, the number of perforated cells decreased (P0.05) in dobutamine group (P0.05). Compared with control group, the number of perforated cells in combination group decreased (P0.05 / 4). The apoptosis rate of A549 cells in dobutamine group was higher than that in dobutamine alone group (P0.05), and the expression level of Yap and P-YAP protein in combination group was higher than that in control group. In dobutamine group and cisplatin group, the expression of YAP in A549 cells decreased, and the expression of P-YAP increased (P0.05). Compared with dobutamine group, the expression of YAP in A549 cells decreased and the expression of P-YAP increased in combination group (P0.05). Conclusion: dobutamine may inhibit the expression of YAP protein in human lung adenocarcinoma cell line A549, and then inhibit the proliferation, migration, invasion and metastasis of A549 cells, and promote the apoptosis of A549 cells.
【學位授予單位】：山西醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R734.2

【參考文獻】

相關期刊論文 前2條

1 Hui-Xia Zheng;Li-Na Wu;Hong Xiao;Qian Du;Jian-Fang Liang;;Inhibitory effects of dobutamine on human gastric adenocarcinoma[J];World Journal of Gastroenterology;2014年45期

2 ;Significance and relationship between Yes-associated protein and survivin expression in gastric carcinoma and precancerous lesions[J];World Journal of Gastroenterology;2009年32期

，

本文編號：2061372